A single-dose, open-label, two-treatment, two-period, two-sequence, two-way cross-over bioavailability & bioequivalence study to compare two formulation of Olmesartan 40 mg in healthy adults in fed state
Authors : Mohit Changani, Ameet Soni, Ambrish Singh, Harsh Choksi, Lokesh Kumar
DOI : 10.18231/j.ijpp.2019.026
